Small Molecules
25 November 2013
Progenics Pharmaceuticals Relaunching Registrational Trial of Azedra to Treat Pheochromocytoma23 November 2013
OLYSIO™ (simeprevir) Receives FDA Approval for Combination Treatment of Chronic Hepatitis C22 November 2013
Tivicay® (dolutegravir) receives positive CHMP opinion in Europe for the treatment of HIV22 November 2013
DelMar Pharmaceuticals Presents Interim Phase 1/2 Clinical Data for VAL-083 in Glioblastoma at Society for Neuro-Oncology Annual Meeting22 November 2013
ARIAD Announces Positive Opinion by the European Medicines Agency on the Continued Availability of Iclusig in Patients with Leukaemias22 November 2013
European CHMP Adopts Positive Opinion for Gilead Sciences’ Sovaldi® for the Treatment of Chronic Hepatitis C Infection22 November 2013
CHMP Determines Dimethyl Fumarate in TECFIDERA® to be a New Active Substance in the European Union22 November 2013
Xigduo™ (dapagliflozin and metformin hydrochloride) Receives Positive CHMP Opinion in the European Union for the Treatment of Type 2 Diabetes22 November 2013
INVOKANA™ (canagliflozin) Approved in the European Union for Treatment of Adults with Type 2 Diabetes22 November 2013
Celgene Receives Positive CHMP Opinion for ABRAXANE® in Combination with Gemcitabine as Treatment for Patients with Metastatic Pancreatic Cancer21 November 2013
GSK and Amicus Therapeutics announce revised Fabry agreement21 November 2013
Pfizer’s XALKORI® Granted Regular FDA Approval21 November 2013
Pfizer and GSK to Initiate Study of Novel Combination Therapy in Patients with Melanoma21 November 2013
D-Pharm starts Phase 2 Clinical Study with DP-b99 in Acute High-Risk Pancreatitis Patients21 November 2013
Cadila Pharmaceuticals launches ‘Mycidac-C’ – First of its kind drug in the world for treatment of Lung Cancer21 November 2013
Forest Laboratories and Gedeon Richter Receive Complete Response Letter for Cariprazine20 November 2013
Tensha Therapeutics Announces First Clinical Trial of BET Bromodomain Inhibitor TEN-010 for Treatment of Cancer20 November 2013
Final results from CLN-14 study in STS19 November 2013
Atopix Therapeutics Recruits First Patient in Phase 2 Trial of OC459 for Atopic DermatitisNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports